Phase 1 Results for ALLO-501 in Non-Hodgkin Lymphoma to be Presented at ASCO
Allogene Therapeutics, a pioneering biotech company in the development of allogeneic CAR-T (AlloCAR T) cancer therapies, in association with Servier, announced that it will have an oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting being held virtually May 29 – May 31, 2020
This will be the first presentation of data from Allogene’s dose escalation Phase 1 ALPHA study of ALLO-501 in relapsed/refractory non-Hodgkin lymphoma (NHL).
ALLO-501 is an anti-CD19 allogeneic CAR T therapy being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. ALLO-501 uses Cellectis technologies. Servier grants to Allogene exclusive rights to ALLO-501 in the U.S. while Servier retains exclusive rights for all other countries.